15 years ago

Horizon Discovery Raises £6.25 Million in Series C Funding

  • Horizon Discovery, a UK-based company specializing in genetically engineered cells and tissues for drug discovery, has secured £6.25 million in Series C funding

  • This investment will support the company's continued growth and development of innovative technologies for the pharmaceutical industry.

      • ProblemHealthcare

      "Traditional drug development is expensive, time-consuming and unpredictable. Patients with rare diseases often don’t have access to the treatments they need. "

      Solution

      "Horizon Discovery uses its cell line engineering expertise to develop accurate and relevant models for drug discovery. This helps pharmaceutical companies to speed up development of new drugs, reduce costs and improve the success rate of clinical trials."

      Covered on